VIROSOMES AS NOVEL DRUG DELIVERY SYSTEM: AN OVERVIEW

Pharma Admission

pharma admission

 

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
Narinder Singh*, Surya Prakash Gautam, NeelamKumari,Rupinder Kaur,Manpreetkaur
CT Institute of Pharmaceutical Sciences, Shahpur, Jalandhar, Punjab
*pharmacist.narinder@gmail.com

ABSTRACT
Virosomes are reconstituted viral envelopes that can fill in as vaccines and as vehicles for cell conveyance of different macromolecules. The prospect of drug delivery and targeting systems utilizing virosomes is an intriguing innovative work field. Since virosomes are biocompatible, biodegradable, non-poisonous and non-autoimmunogenuic; endeavors have been made to use them as antibodies or adjuvants and also conveyance frameworks for drugs and organic for remedial purposes. The achievement of virosomal medicate conveyance relies on upon strategy used to set up the typified bioactive materials and fuse them into the virosomes. Virosome innovation could conceivably be utilized to convey peptides, nucleic acids or, then again qualities and medications like anti-toxins, anticancer agents, and steroids.

Reference Id: PHARMATUTOR-ART-2538

PharmaTutor (Print-ISSN: 2394 - 6679; e-ISSN: 2347 - 7881)

Volume 5, Issue 9

Received On: 30/06/2017; Accepted On: 20/07/2017; Published On: 01/09/2017

How to cite this article: Singh N, Gautam SP, Kumari N, Kaur R, Kaur M;Virosomes as Novel drug delivery System: An Overview; PharmaTutor; 2017; 5(9);47-55

INTRODUCTION
The Novel invention of therapeutics against neurodegenerative or cancer disorders involve delivery systems to facilitate target drugs toward particularhost tissues and cell types by controlled release and receptor-mediated uptake. Virosomal technology present anovel difficult delivery system towardconvenethese confront. Toward enhance the effectiveness of gene delivery through the beginning of molecules directly into cells.Virosomes has been developed in combining various agents like antigen, drug and DNA amongfusiongenic viral cover proteins.[1]
The Enhancement of delivery competence in vivo is a major objective in the field of virosomes research. In spite of improvements in non-viral and viral vector systems, major hurdle in the delivery of drugs and other macromolecules into the preferred cell category is crossing the permeability barrier imposed by the plasma membrane followed by the controlled release inside the cytoplasm. Virosomes are regenerateempty influenza virus envelopes. Wherever infectious neuclocapside be replaced by compound of choice. Virosomes are not replicate but they are pure fusion activity vesicles thus deliver the incorporated compound such as drug, antigen, genes inside the target cell. Virosomes protect pharmaceutically active substances from proteolytic degradation and low pH within endosomes, allowing their contents to remain intact when they reach the cytoplasm.[5]The virosome carrier systemin excess ofnewly drugdeliveryvehicles like proteoliposomal and liposomal carrier systems.

Virosome Structure
Virosomes are consist of spherical or unilamellar phospholipidbilayervesicle having meandiameter in the range of 120-180nm. Influenza virus is most commonly used for virosome production and genetic material of the sourcevirus. Virosomesarenotcap able to replicate other thanpurefusion active vesicles are presents.

Structure of Virosome
The Virosomemainly constituentsof Immune stimulating Regenerate Influenza Virosomes (IRIVs) consist of naturally occurring phosphatidylcholine (PC) and phospholipids(PL). PC formsaround 70% of the virosomal structure. The left behind 30%of membrane components has the envelopephospholipids originating from the influenza virus to facilitate provide haemagglutinin(HA) and neuraminidase (NA) glycoproteins.Virosomes canbe optimized used for maximal inclusion of thedrug or for the greatest physiological effect bymodifying the content or else type of membranelipids used. It is even possible to generatecarriers for antisense-oligonucleotides orothersome genetic molecules depending onwhether positively or negatively loadedphospholipids are included into themembrane. Various ligandslike peptides, cytokines, and monoclonalantibodies (MAbs) can be incorporated intothe virosome. It also displayed on the virosomalsurface. Tumor-specific monoclonalantibody fragments (Fab) might be linked tovirosomes to direct the carrier to selectedtumor cells.

Figure no.1: Structure of Virosome

Preparation of Virosome
1.    Selection of virus
Virosome are recons titute dviralenvelop which have consequent from different virus. Influenza virus envelope is most of ten used to produce virosome but virosome can also be made from Sendai virus, sindbis, Epstein-burrvirus, friendmurine leukemia virus, herpes simplex virus.[2]

2.    Selection ofantigen
Antigen is preferred as per our necessities.Antigenswhich are used like abacterium parasite, carcinogenic cell, orwholecell is used as antigens. Cell components includeRNA, DNA, or plasmid could also be used as antigen.[3]

3.  Reconstituted of virosome
Virosome solubilized with detergent such as (octaglucoside, nonidert p-40). Due to solubilization with detergent genetic material and internal viral protein will sediment afterward detergent is removed by different method like hydrophobic resins and dialysis from supernatant. By uses ultracentrifugation development viral matrix protein and nuclei capsid is removed. Antigen which has coupled to lipid anchor is mixed with surfactant or polymersolution. This solution is processamong virosome mover antigen bound virosome is achieved.[4]

NOW YOU CAN ALSO PUBLISH YOUR ARTICLE ONLINE.

SUBMIT YOUR ARTICLE/PROJECT AT editor-in-chief@pharmatutor.org

Subscribe to Pharmatutor Alerts by Email

FIND OUT MORE ARTICLES AT OUR DATABASE


Pages

FIND MORE ARTICLES